RecruitingNot applicableNCT06169852
Stimulus-Evoked Directional Field Potentials to Guide Subthalamic and Pallidal DBS for PD
Sponsor: University of Alabama at Birmingham
Birmingham, AL
Parkinson's Disease clinical trials
257 recruiting studies in the US for parkinson's disease, a movement disorder of the nervous system.
Parkinson's research blends Phase 1 and 2 studies of therapies that may slow progression with many exercise, speech, device and imaging studies. Some drug trials look for people diagnosed recently and not yet on medication, while others enroll people with longer-standing disease. A care partner is often welcome at visits.
Top locations
By phase
Showing 40 of 257 studies
RecruitingPhase 3NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Sponsor: Merck Sharp & Dohme LLC
Bakersfield, CA · Beverly Hills, CA · Stamford, CT · +12 more sites
RecruitingNot applicableNCT07883720
EXercise-induced PhysioLogical Adaptations In Neurological Disorders
Sponsor: Brigham and Women's Hospital
Boston, MA
RecruitingPhase not listedNCT00060541
Evaluation and Treatment of Neurosurgical Disorders
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, MD
RecruitingPhase 1NCT05152394
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease
Sponsor: The Foundation for Orthopaedics and Regenerative Medicine
Naples, FL
RecruitingPhase 1NCT06565195
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
Sponsor: Prevail Therapeutics
Englewood, CO · New Haven, CT · Naples, FL · +4 more sites
RecruitingPhase not listedNCT03019757
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
Sponsor: Douglas Scharre
Columbus, OH
RecruitingPhase 3NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Sponsor: Merck Sharp & Dohme LLC
Phoenix, AZ · Burbank, CA · Grand Junction, CO · +12 more sites
RecruitingNot applicableNCT06993142
Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage
Sponsor: Radboud University Medical Center
Rochester, NY
RecruitingPhase 4NCT07138560
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
Sponsor: The Cleveland Clinic
Cleveland, OH
RecruitingPhase 1NCT06809400
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Sponsor: Eli Lilly and Company
Los Alamitos, CA · Maitland, FL · +9 more sites
RecruitingNot applicableNCT07701785
Superior Parietal iTBS for PD-MCI
Sponsor: Medical University of South Carolina
Charleston, SC
RecruitingPhase not listedNCT02071134
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Sponsor: Boston Scientific Corporation
Aliso Viejo, CA · Los Angeles, CA · Aurora, CO · +26 more sites
RecruitingPhase not listedNCT04997642
Parkinson's Disease and Movement Disorders Clinical Database
Sponsor: University of Pennsylvania
Philadelphia, PA
RecruitingPhase 3NCT06312176
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Sponsor: Merck Sharp & Dohme LLC
Chandler, AZ · Gilbert, AZ · Fullerton, CA · +43 more sites
RecruitingPhase 3NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Sponsor: Merck Sharp & Dohme LLC
Mobile, AL · Chandler, AZ · Duarte, CA · +36 more sites
RecruitingPhase 3NCT06966700
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Sponsor: Merck Sharp & Dohme LLC
Gilbert, AZ · Phoenix, AZ · Tucson, AZ · +61 more sites
RecruitingPhase 3NCT06989112
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Sponsor: AstraZeneca
Tucson, AZ · Little Rock, AR · Duarte, CA · +60 more sites
RecruitingPhase 3NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Sponsor: Merck Sharp & Dohme LLC
Birmingham, AL · Anchorage, AK · Irvine, CA · +27 more sites
RecruitingPhase not listedNCT07428447
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
Sponsor: CND Life Sciences
Scottsdale, AZ · Orlando, FL · +5 more sites
RecruitingPhase not listedNCT07868614
Intraoperative Microelectrode Recordings Using MAVEN Compared to Standard Recording Apparatuses
Sponsor: Mayo Clinic
Rochester, MN
RecruitingNot applicableNCT01581580
Deep Brain Stimulation Surgery for Movement Disorders
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, MD
RecruitingPhase 2NCT05700825
Rehabilitation of Airway Protection in Parkinson's Disease
Sponsor: Teachers College, Columbia University
West Lafayette, IN · New York, NY
RecruitingPhase not listedNCT06960096
Cognitive Decline Following Deep Brain Stimulation: A DBS-fMRI Study
Sponsor: Medical University of South Carolina
Charleston, SC
RecruitingPhase 2NCT06996652
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
Sponsor: Yale University
Los Angeles, CA · Aurora, CO · North Haven, CT · +15 more sites
RecruitingPhase not listedNCT03664609
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
Sponsor: Boston Scientific Corporation
Phoenix, AZ · Moreno Valley, CA · San Francisco, CA · +7 more sites
RecruitingPhase 1 / Phase 2NCT05319730
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Sponsor: Merck Sharp & Dohme LLC
Tucson, AZ · Los Angeles, CA · East Syracuse, NY · +2 more sites
RecruitingPhase 1 / Phase 2NCT06469944
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Sponsor: Merck Sharp & Dohme LLC
Tucson, AZ · Los Angeles, CA · Louisville, KY · +5 more sites
RecruitingPhase 1 / Phase 2NCT07863180
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
Sponsor: Prabesh Kanel
Ann Arbor, MI
RecruitingPhase not listedNCT06405334
Kinematic and Neural Dynamics of Postural Instability in Parkinson's Disease
Sponsor: VA Office of Research and Development
Minneapolis, MN
RecruitingPhase 3NCT07174310
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Sponsor: Hoffmann-La Roche
Birmingham, AL · Phoenix, AZ · Fullerton, CA · +50 more sites
RecruitingPhase 2NCT07432958
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Sponsor: Appello Pharmaceuticals, Inc.
Little Rock, AR · Carlsbad, CA · Los Alamitos, CA · +27 more sites
RecruitingPhase 1NCT07161414
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
Sponsor: AstraZeneca
Huntersville, NC · San Antonio, TX · Fairfax, VA
RecruitingPhase 2NCT06680830
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Sponsor: Neuron23 Inc.
Sun City, AZ · Little Rock, AR · Fresno, CA · +42 more sites
RecruitingNot applicableNCT04957095
Motor Network Physiology
Sponsor: University of Texas Southwestern Medical Center
Dallas, TX
RecruitingPhase 2NCT06780085
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Sponsor: Merck Sharp & Dohme LLC
Lexington, KY · Baltimore, MD · Pittsburgh, PA
RecruitingPhase not listedNCT07849413
Visual Hallucinations in Lewy Body Diseases
Sponsor: NYU Langone Health
New York, NY
RecruitingPhase 2NCT06961006
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Sponsor: Merck Sharp & Dohme LLC
Springdale, AR · San Francisco, CA · Hackensack, NJ · +2 more sites
RecruitingPhase 2 / Phase 3NCT06976268
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Sponsor: Biohaven Therapeutics Ltd.
Birmingham, AL · Irvine, CA · Los Angeles, CA · +21 more sites
RecruitingPhase 2NCT07610369
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Sponsor: Yale University
New Haven, CT
Related conditions
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.